GleamWall
中文EN

PLYX Polaryx Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2075320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-114.9%
ROA-101.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.6%
Debt / equity0.00x
Current ratio8.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue———————
R&D expense$2.45M$719,000$679,000$560,000$514,000$476,000$4.72M
SG&A expense$877,000$661,000$1.28M$351,000$460,000$408,000$336,000
Operating income-$3.33M-$1.38M-$1.96M-$911,000-$974,000-$884,000-$5.05M
Net income-$3.33M-$1.38M-$2.54M-$1.50M-$1.43M-$1.01M-$5.05M
EPS (basic)-0.07-0.03-0.05—-0.03-0.02-0.11
EPS (diluted)-0.07-0.03-0.05—-0.03-0.02-0.11
Weighted avg. shares (diluted)49.85M48.28M47.22M—45.79M44.67M44.34M
Balance sheet
Cash & equivalents$8.44M$11.54M$3.08M$5.14M———
Current assets$8.61M$11.81M$3.50M$5.17M———
Total assets$8.61M$11.81M$3.50M$5.17M———
Current liabilities$999,000$873,000$1.01M$605,000———
Total liabilities$999,000$873,000$1.01M$605,000———
Shareholders' equity$7.61M$10.94M$2.49M$4.57M$5.30M$3.25M$4.25M
Shares outstanding49.85M49.85M47.34M47.34M———
Cash flow statement
Operating cash flow-$3.10M-$1.37M-$2.06M-$1.49M-$887,000-$858,000-$709,000
Financing cash flow$0——$888,000$3.33M$0$250,000
Stock-based compensation$0$0$467,000$57,000$108,000$109,000$4.45M

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.